Quince Therapeutics (NASDAQ:QNCX) Stock Price Expected to Rise, D. Boral Capital Analyst Says

Quince Therapeutics (NASDAQ:QNCX) had its target price lifted by equities research analysts at D. Boral Capital from $4.00 to $5.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. D. Boral Capital’s target price would suggest a potential upside of 35.14% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Quince Therapeutics in a research report on Monday, December 8th. Zacks Research upgraded Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.20.

Quince Therapeutics Trading Down 1.9%

NASDAQ:QNCX opened at $3.70 on Monday. The stock has a market capitalization of $206.02 million, a P/E ratio of -3.06 and a beta of 1.03. Quince Therapeutics has a 1 year low of $0.72 and a 1 year high of $4.55. The firm has a 50 day moving average of $2.41 and a 200-day moving average of $1.88.

Quince Therapeutics (NASDAQ:QNCX) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). As a group, analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC grew its holdings in Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock valued at $58,000 after purchasing an additional 14,128 shares during the period. Bridgeway Capital Management LLC grew its holdings in shares of Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after buying an additional 22,200 shares during the period. XTX Topco Ltd bought a new stake in shares of Quince Therapeutics in the 2nd quarter valued at $37,000. GSA Capital Partners LLP increased its position in shares of Quince Therapeutics by 158.0% in the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after buying an additional 53,417 shares in the last quarter. Finally, Union Square Park Capital Management LLC raised its stake in Quince Therapeutics by 86.0% during the 3rd quarter. Union Square Park Capital Management LLC now owns 224,746 shares of the company’s stock worth $366,000 after buying an additional 103,889 shares during the period. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.